



Zoster Vaccines Session: Introduction

ACIP Meeting

September 29, 2021


Camille Nelson Kotton, MD
Chair, Herpes Zoster Work Group

2021 Herpes Zoster Work Group

ACIP Members	
Camille Nelson Kotton, MD (Chair)	
Lynn Bahta, RN, MPH	
Grace Lee, MD, MPH	
Ex Officio Members	
Paula Agger, MD, MPH	FDA
Jeffrey Cohen, MD	NIH
Darcie Everett, MD, MPH	FDA
Jeffrey Kelman, MD	CMS
Liaison Representatives	
Carol Baker, MD	IDSA
Mary Pat Friedlander, MD	AAFP
Sandra Fryhofer, MD	ACP/AMA
Elizabeth Rausch-Phung, MD, MPH	AIM
William Schaffner, MD	NFID
Kenneth Schmader, MD	AGS
Adam Welch, PharmD	APhA

Invited Consultants
Edward Belongia, MD
Al Benson, MD
Paul Cieslak, MD
Jeffrey Curtis, MD, MPH
Jay Fishman, MD
Rafael Harpaz, MD, MPH
Kelly Moore, MD, MPH
Vicki Morrison, MD
Steven Pergam, MD
Lisa Prosser, PhD
CDC Lead
Tara Anderson, DVM, MPH, PhD

Timeline of Recombinant Zoster Vaccine (RZV, Shingrix)



Abbreviations: HZ-Herpes Zoster; IC-Immunocompromised; RZV-Recombinant Zoster Vaccine; EtR-Evidence to Recommendations Framework

Policy Question

- **Should adults ≥ 19 years of age who are or will be immunodeficient or immunosuppressed due to disease or therapy be recommended to receive two doses of recombinant zoster vaccine for the prevention of herpes zoster and its complications?**

- **Including but not limited to:**
 1. Hematopoietic stem cell transplant (HSCT) recipients
 2. Patients with hematologic malignancies (HM)
 3. Renal or other solid organ transplant (SOT) recipients
 4. Patients with solid tumor malignancies (STM)
 5. People living with HIV
 6. Patients with primary immunodeficiencies, autoimmune conditions, and taking immunosuppressive medications/therapies

PICO Question

Population	Immunocompromised (IC) adults ≥ 19 years of age
Intervention	Recombinant zoster vaccine (RZV), 2 doses at least 4 weeks apart
Comparison	No vaccine
Critical Outcomes	<ul style="list-style-type: none">• Prevent Herpes Zoster (HZ)• Serious Adverse Events (SAEs)
Important Outcomes	<ul style="list-style-type: none">• Prevent Postherpetic Neuralgia (PHN)• Prevent HZ-Related Hospitalization• Immune-Mediated Disease (IMD)• Reactogenicity (Grade 3)• Graft versus Host Disease (HSCT)• Graft Rejection (SOT)

June 2021 ACIP Meeting

- Burden of HZ in IC adults
- Use of RZV in IC populations: an overview of GSK's clinical program

EtR Domain	Question
Public Health Problem	Is the problem of public health importance?
Benefits and Harms	How substantial are the desirable anticipated effects?
	How substantial are the undesirable anticipated effects?
	Do the desirable effects outweigh the undesirable effects?
Values	Does the target population feel the desirable effects are large relative to the undesirable effects?
	Is there important variability in how patients value the outcomes?
Acceptability	Is the intervention acceptable to key stakeholders?
Feasibility	Is the intervention feasible to implement?
Resource Use	Is the intervention a reasonable and efficient allocation of resources?
Equity	What would be the impact of the intervention on health equity?

Activities since June 2021 ACIP Meeting

- **Four work group meetings**
- **Reviewed and discussed**
 - Remaining EtR domains
 - Economic assessment of herpes zoster vaccination of IC populations who are 19–49-years-old
 - Primary care physicians' perspective related to RZV
 - GRADE analysis regarding use of RZV in IC adults
 - Special considerations for potential use of RZV in IC adults

Today's Session

- **Economics of vaccinating immunocompromised 19–49-year-old adults against herpes zoster in the US**
- **Preliminary EtR regarding use of RZV in immunocompromised adults and next steps**
- **Discussion**

Acknowledgments

- **ACIP HZWG:** Paula Agger, Robin Avery, Lynn Bahta, Carol Baker, Edward Belongia, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Grace Lee, Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill Schaffner, Ken Schmader, Adam Welch
- **HZWG CDC Lead:** Tara Anderson
- **CDC, Other Contributors:** Jessica Anderson, Stephanie Bialek, Doug Campos-Outcalt, Tom Clark, Amanda Cohn, Janine Cory, Kathleen Dooling, Jonathan Duffy, Richard Forshee, Jack Gersten, Angela Guo, Theresa Harrington, Alexandra Hess, Laura Hurley, Shainoor Ismail, Lisa Jackson, Tara Jatlaoui, Andrew Kroger, Andrew Leidner, Jessica Leung, Megan Lindley, Jessica MacNeil, Mona Marin, Karen Mason, Nina Masters, Rebecca Morgan, Jennifer Nelson, Ismael Ortega-Sanchez, Paul Rota, Coleman Rotstein, Jeanne Santoli, Leah Shepersky, Tom Shimabukuro, John Su, Joanna Taliano, Megan Wallace, Eric Weintraub

Thank You

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

